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Introduction 1
In resource-limited settings, noncompetitive HIV-1 reverse transcriptase inhibitors 2 (NNRTI) are the WHO recommended backbone of first-line antiretroviral therapy. 3
Nevirapine in combination with two nucleoside analog inhibitors of reverse transcriptase 4 such as stavudine, or zidovudine, in addition to lamivudine was, at the time of the study, 5 the recommended antiretroviral regimen in treatment-naïve patients, mainly because of the 6 availability of WHO prequalified low-cost generic fixed-dose combination (7, 27) . In 7 Cambodia, the prevalence of HIV infection among the general population aged between 15 8 and 49 years peaked at 2% in 1998 and had declined to 0.9% in 2006. This decrease has 9 been attributed to many deaths among people infected during the early years of the 10 epidemic before implementation of the continuum of care and the scaling-up of HIV 11 prevention, care and treatment programs. At the end of 2009, it is estimated that about 12 37000 patients were on antiretroviral drug regimens and 69.5% were on a nevirapine 13 backbone regimen (NCHADS source at http://www.nchads.org/). 14 Therefore, worldwide, most patients living with AIDS and who need antiretroviral 15 treatment are on a nevirapine-based antiretroviral regimen. However, data on factors 16
influencing its pharmacokinetics and exposure in different populations are lacking. 17 Nevirapine pharmacokinetics is characterized by a long half-life, 60% binding to plasma 18 proteins and elimination mainly through oxidative metabolism involving CYP3A and 19 CYP2B6 (14) . Both CYP3A4 and CYP3A5 share substrates and their role in nevirapine 20 metabolism is not clearly defined. The importance of CYP2B6 genetic polymorphism in 21 efavirenz metabolism is now well established, but its influence on nevirapine metabolism is 22 less clear (21) . One study suggests that nevirapine could be a weak substrate of the P-23 glycoprotein efflux transporter (1) . CYP3A5, CYP2B6 and ABCB1 (MDR1, which endcodes 1 for P-glycoprotein) are known to be highly polymorphic (http://www.cypalleles.ki.se/, 2 (46) ). The following genetic polymorphisms were therefore studied. The CYP3A5*3 allele 3 (G at position 6986) creates a cryptic splice site creating aberrant mRNA, with a premature 4 stop codon. Individuals with at least one A allele (CYP3A5*1) produce high levels of full-5 length CYP3A5 mRNA and express an active CYP3A5 enzyme, while those carrying the 6 CYP3A5 6986 GG (CYP3A*3) genotype have very low or even undetectable hepatic 7 CYP3A5 protein content. The two most relevant SNPs of CYP2B6 (CYP2B6 G516T and 8 C1459T) were demonstrated to result in a significant decrease in protein expression. 9
ABCB1 3435 C>T was associated with decreased transport function. Consequently 10 homozygous CYP3A5 6986GG, CYP2B6 516TT or 1459TT and ABCB1 3435TT alleles are 11 associated with loss of function protein. 12 The aims of this descriptive study were to characterize nevirapine pharmacokinetic 13 parameters in a large Cambodian population of HIV-infected patients using a population 14 approach and to identify environmental and genetic factors of variability focusing on the 15 CYP3A5, CYP2B6 and ABCB1 (MDR1) genes. Mixed effect models were used due to their 16 flexibility in handling balanced and unbalanced data in a unified framework (37) 17
Methods

18
Patients and study design 19 The patients enrolled in this open-label, single-center, multiple-dose pharmacokinetic study 20 were HIV-infected Cambodians. They have been included in the Esther cohort at the 21 Calmette Hospital (Phnom Penh) since 2003, when treatment and care have been provided  22  to  patients  living  with  AIDS  in  Cambodia.  This  additional  1 pharmacokinetic/pharmacogenetic study was approved by the National Ethics Committee 2 of Cambodia. All patients signed an informed consent form which was explained orally in 3 presence of a witness for those unable to read. To be included in the study, patients have 4 consented to have an additional blood sample drawn at the 3-year evaluation for 5 pharmacogenetics. During the first year about 300 HIV-infected patients were included in 6 this cohort, most of them treated with a nevirapine + lamivudine + stavudine generic fixed-7 dose combination. Patients were treated with nevirapine 200 mg daily for the first two 8 weeks and 200 mg bid thereafter in addition to stavudine 30 mg bid and lamivudine 150 9 mg bid. After 18 months of treatment, stavudine was switched to zidovudine 300 mg bid in 10 most patients. Patients came to the clinic monthly for medical consultation and drug refill. 11
They had to participate to at least three specific adherence consultations by a trained nurse. 12
All patients were routinely monitored every six months for standard liver and renal 13 function tests and CD4 cell count (Cyflow, Partec, Germany) in blood. As part of the 18-14 month (M18) and 3-year (M36) visits for evaluation of treatment efficacy, in addition to 15 standard laboratory tests, plasma HIV RNA (41) and nevirapine plasma trough 16 concentration before morning drug intake were measured. Samples drawn 12±2h after 17 evening drug intake were kept for pharmacokinetic analysis. Adherence to antiretroviral 18 therapy was monitored using a validated visual analog scale (2) . Some of the patients were 19 tested for HCV and HBV. In addition to the M18 and M36 sampling, ten patients agreed to 20 participate in an extensive pharmacokinetic substudy. They fasted under a steady-state 21 regimen before antiretroviral drug administration and blood samples were collected at 22 predose and at 1 h, 2 h, 4 h, 8 h after the nevirapine morning intake. 23 1 Genotyping 2 DNA was extracted from patient blood by using the QUIamp® DNA Mini Kit according to 3 the protocol of the manufacturer (Qiagen). Genotyping for CYP3A5 6986A>G (rs776746), 4 CYP2B6 516G>T (rs3745274), CYP2B6 1459C>T (rs3211371), and ABCB1 3435C>T 5 exon26 (rs1045642) was performed using the TaqMan allelic discrimination assay (ABI 6 prism 7000, Applied Biosystems, Courtaboeuf, France). Primers and probes used for 7 ABCB1, CYP3A5 SNPs detection have been described previously (10, 39). CYP2B6 8 genotyping was performed with the use of TaqMan validated SNP assays 9 (C___7817765_60 C__30634242_40 ) with the 7000HT Sequence Detection System 10 (Applied Biosystems). Reactions were carried out as described previously (10, 39) . 11
For each polymorphism, departure from Hardy-Weinberg proportions was tested using a χ 2 12 test with degrees of freedom equal to the number of observed genotypes minus 1. 13 15 Plasma nevirapine concentrations were assayed in France (M18) or Cambodia (M36) by 16 liquid chromatography with diode array detection at 240 nm according to previously 17 validated assays (48). The lower limit of quantification was 50ng/mL. Standard curves 18 were linear up to 10000ng/mL. The within-day and day-to-day precisions of quality control 19 samples included in each analytical run were below 9%. Both laboratories participate in the 20 French program of external quality controls (Asqualab). 21
14
Assay of nevirapine in plasma
22
Population pharmacokinetic analysis 1 Population pharmacokinetic modeling was performed using MONOLIX software version 2 2.4 (http://software.monolix.org/). A one-compartment model at steady state with first-3 order absorption and elimination parameterized in apparent volume of distribution (V/F) 4 and clearance (CL/F) was used to describe the nevirapine concentrations. Data below the 5 limit of quantification (50 ng/mL) were discarded from the analysis. Given the expected 6 concentration levels, a patient with a concentration below this limit might be assumed not 7 to have taken his pills. 8
In a first step, the interpatient variance matrix and the residual error model were determined 9 with data from the 10 patients of the extended pharmacokinetic study plus the M36 10 nevirapine trough concentrations. The Bayesian information criterion (BIC) was used to 11 select the residual error model (combined, proportional or constant) and the non-null 12 interpatient variances (6). In a second step, the concentrations collected at the M18 13 evaluation were added to the previous data set and intrapatient (e.g. interoccasion) 14 variances (γ 2 ) were added to parameters with non-null interpatient variances (ω 2 ). To model 15 interpatient and intrapatient variabilities we used an exponential model with Gaussian 16 random effects. 17
In order to assess to what extent a model parameter is likely to be under the influence of 18 genetic polymorphisms, the genetic component of the variability R GC was computed as 19 described by Ozdemir et al (35):
which gets closer to one as the parameter is 20 likely to be influenced by genetic polymorphisms. 21
The continuous covariates investigated were age, weight, ALAT, plasma creatinine, 1 creatinine clearance, plasma HIV RNA, CD4 count and adherence (assessed using a visual 2 analog scale) along with sex, co-treatment (stavudine or zidovudine), plasma HIV RNA 3 above 400 copies/mL, HCV coinfection, HBV coinfection and genotype for the CYP3A5 4 inflation that has been shown to occur in such designs (5) . One thousand permutations were 16 performed to insure the nominal level of 0.05. 17
The average nevirapine clearance for each patient was computed as the mean over the 18 empirical estimates at the different occasions. Simulations based on the final 19 pharmacokinetic estimates were performed with R software v2.9.1 (http://cran.r-20 project.org/) using 250 data sets to calculate the predicted 90% interval and median which 21 were overlaid on the observed data on a visual predictive check plot. These simulations 22
were also used to compute normalized prediction discrepancies using the R package 1 (http://www.npde.biostat.fr/) to be plotted versus time. 2 in addition to the pharmacogenetic study. In addition, 10 patients (5 men) participated in 9 the extensive pharmacokinetic substudy and only 3 did not participate in the M18 or M36 10 evaluation. The patient's demographic and laboratory data are listed in Table I Nevirapine exposure 1 Four patients had concentrations measured at M18, M36 and in the extensive 2 pharmacokinetic substudy, 136 patients had concentrations at both M18 and M36 and 29 3 patients had concentrations at only one of these evaluations. At M18 one patient was 4 excluded from the analysis as the only concentration was below the limit of quantification 5 (LOQ), three other concentrations were below the LOQ, two at M18 and one at M36. 6 Figure 1 represents the nevirapine concentrations observed at each occasion. The median 7 nevirapine trough concentrations were 5705 ng/mL (≤50 ─ 13871 ng/mL) and 5709 ng/mL 8 (≤50 ─ 15422 ng/mL) at M18 and M36, respectively. Note that 3.4% and 5.6% of the 9 patients had nevirapine trough concentrations below 3000 ng/mL at M18 and M36, 10 respectively. 11 12 Population pharmacokinetics of nevirapine 13 Nevirapine concentrations were adequately described by a one-compartment model with 14
Results
3
Characteristics of the study population
first order absorption and elimination. With the basic model, the apparent clearance of 15 nevirapine was estimated to be 2.67 L/h with an interpatient variability of 28% and an 16 intrapatient variability of 17%. The absorption constant and the apparent volume of 17 distribution were 1.64 /h and 213 L (on average 3.9 L/kg), respectively. Adding interpatient 18 variabilities to these parameters did not improve the model. A constant residual error model 19 was selected, with an estimated standard deviation of 519 ng/mL. The estimates from the 20 basic model as well as their relative estimation error (%) are given in Table II.  21 The genetic component of variability, R GC , for nevirapine clearance was 63.1%. After the 22 first step of univariate covariate selection, CYP2B6 516G>T polymorphism (P=0.02 and 23 3.10 -10 for the GT and TT genotypes; respectively; compared with GG), creatinine 1 clearance (P=0.07) and HCV coinfected status (P=0.04) were significantly associated with 2 the nevirapine apparent clearance (at the 0.1 level). Interestingly, in liver function tests 3
ALAT was not found to be a significant covariate. 4
Following the ascendant procedure based on the Wald test, only the effect of the CYP2B6 5
516G>T genetic polymorphism and the creatinine clearance remained in the model so that 6 the apparent clearance of subject i at occasion k is predicted as 7
where β i =0, -0.12 or -0.46 if patient i is GG, GT or TT for the CYP2B6 516G>T genetic 10 polymorphism, and CLCR ik is his creatinine clearance at occasion k. 11 P-values of the permutation test were 0.01 for GT versus GG, 0.001 for TT versus GG and 12 0.007 for creatinine clearance. Estimates from the final model and their 95% confidence 13 interval derived from the standard errors are given in Table II. The population mean  14 clearance was estimated to be 2.95 L/h, 2.62 L/h and 1.86 L/h for patients carrying GG, GT 15 and TT genotypes for the CYP2B6 516G>T polymorphism, which corresponds to 11% and 16 37% decreases in clearance from the GG to the GT and TT genotype, respectively. The 17 lowest value of creatinine clearance was associated with a 14% decrease in CL/F, whereas 18 the highest value of creatinine clearance was associated with a 16% increase in CL/F. The 19 addition of the polymorphism and the creatinine clearance to the model lowered the 20 interpatient variability by 3.1 and 0.3%, respectively. 21 These are the first results on frequencies of genetic polymorphism of major drug 8 metabolizing enzymes and transporters reported to be involved in NNRTI disposition in a 9 large Cambodian population. Most Caucasian expressed the CYP3A5 6986GG genotype 10 associated with a small amount of translated CYP3A5 protein with a G allele frequency 11 ranging from 0.87 to 0.94 in various Caucasian populations (22, 29) . In contrast, in various 12
Asian populations G allele frequencies were lower ranging from 0.59 in Indians to 0.65 in 13
Cambodians as demonstrated in this study, 0.67 in Vietnamese and 0.74-0.78 in Japanese, 14
Chinese and Koreans (23, 29) . The frequency is even lower in patients of African descent 15 (0.36) (22) . Higher expression of CYP3A5 protein will lead to an increase in clearance of 16
CYP3A substrate drugs such as HIV-1 protease inhibitors. Lower saquinavir, atazanavir or 17 indinavir concentrations (3, 24, 44) were demonstrated in patients who express CYP3A5, 18 although disposition of lopinavir combined with ritonavir, which inhibits both CYP3A4 19 and CYP3A5, remains unaffected (15) . This is of importance as lopinavir/ritonavir is the 20 antiretroviral drug recommended by WHO for patients in whom a first-line NNRTI 21 regimen fails. 22
The frequency of the CYP2B6 516G>T mutant allele associated with loss of catalytic 1 activity varies greatly according to the study population, with the following average values: The population pharmacokinetics of nevirapine was studied in a Cambodian HIV-infected 17 population after long-term administration of nevirapine as backbone antiretroviral first-line 18 therapy. The impressive efficacy of this antiretroviral drug regimen is in keeping with 19 previous studies (7, 27). Such a positive virological outcome has already been pointed out 20 in another Cambodian cohort with an efavirenz-based regimen (16) was related to high 21 adherence to cART, as noted by Spire et al (45) . In the present study most patients (99%) 22
reported an adherence greater than or equal to 8 on a 10-point visual analog scale. It should 23 be stressed that in both cohorts antiretroviral therapy was provided free through Global 1 Funds and NCHADS programs and that educational programs were implemented on a 2 regular basis. 3
Although nevirapine is the antiretroviral drug of choice in low income countries, little is 4 known of between-and within-patient variability. Our data show that after more than one 5
year, under steady-state conditions, intraindividual variability in trough nevirapine 6 concentrations is quite low, in agreement with previous data as Nettles et al indicated a 7 within-patient variability of 25% in one patient who received nevirapine, which is well 8 below what has been reported for HIV-protease inhibitors (19, 34) . This is in keeping with 9 nevirapine pharmacokinetic properties, with an absolute bioavailability reported to be 90% 10 after single-dose administration (26). Half-life at steady state is longer than the dosing 11 interval in most patients despite autoinducing properties, which means that delaying drug 12 intake or missing a dose will have little influence on steady-state concentrations. 13
Interpatient variability is also quite low, most likely because absorption variability can be 14 ruled out. Interestingly, Manosuthi et al (30) recently reported that interpatient variability 15 in the efavirenz group was 2.3-fold greater than in the nevirapine group, although these 16 patients received concomitant use of rifampicin which could alter variability. 17
Estimation of nevirapine Cl/F calculated at steady state in our population is in the range, 18 albeit somewhat lower, of values in previous studies including different populations (2.95 19 to 3.35 L/h, (11-13, 17, 33, 42, 50) and is roughly twice the apparent clearance reported 20 after single-dose administration (21, 31) , which clearly shows the importance of the 21 autoinducing effect either on first-pass effect and bioavailability or total clearance. The 22 95% confidence interval for the apparent volume of distribution is large (111 -446 L) as 23 the estimation error of this parameter is high. Therefore comparison with other studies 1 reporting somewhat lower values is difficult (21, 31) . Interpatient variability in V/F and k a 2 could also not be estimated. This and the large standard error in V/F are related to the study 3 design, since in most patients only one trough concentration was measured at each 4 evaluation, giving mostly information on apparent clearance. This is the one of the few 5 studies demonstrating that CYP2B6 516G>T genetic polymorphism and creatinine 6 clearance affect nevirapine clearance, but explains only 3.1% and 0.3% of the interpatient 7 variability, respectively. Apparent clearance is decreased by 37% in homozygous patients 8 carrying the loss of function allele compared with the homozygous wild-type allele, which 9 leads to an increased half-life estimated to be 52 h (range 28 -96h) for GG, 59 h (29 - been reported in patients with the CYP2B6 516TT genotype (28, 36, 40) , although the 14 relationship is unclear after single-dose administration (9, 21) . Such a discrepancy could be 15 related to the autoinduction of CYP2B6 by repeated administration of nevirapine. 16
Interestingly, genetic polymorphism was not found to affect the volume, ruling out a large 17 inducing effect on bioavailability and first-pass effect. A relationship between nevirapine 18 clearance and creatinine clearance was unexpected as nevirapine is eliminated mostly by 19 biotransformations. Such a relationship was noted by Gandhi et al (17) in a cohort of HIV-20 infected women and they suggested that the effect of uremic toxins on relevant hepatic 21 transporters and metabolizing enzymes may explain the influence of renal insufficiency on 22 nevirapine clearance. However, the clinical relevance of this phenomenon is small as the 23 major changes were less than 20% from the mean. In agreement with others, no 1 relationship between nevirapine clearance and weight was evidenced (11, 22) 2
No modification in nevirapine pharmacokinetics was seen in patients with liver disease (8, 3 11) and no relationship between ALAT and nevirapine concentrations was found in the 4 present study. 5
This study has a number of limitations. First, plasma HIV RNA was not measured at 6 inclusion in the cohort as this parameter was not available in Cambodia when the Esther 7 cohort was initiated. Therefore, no relationship between plasma HIV RNA decline and 8 nevirapine exposure could be established. Treatment failure was only seen in a few 9 antiretroviral-naïve patients at the first evaluation, which would have made such a 10 relationship difficult to demonstrate. Second, patients who developed rashes and liver 11 toxicity early after initiating treatment were switched to efavirenz, so it cannot be shown 12 whether the frequency of occurrence of these adverse events is dependent on the ABCB1, 13 CYP3A5 or CYP2B6 loss of function allele. Third, it remains to be seen whether other 14 infrequent variants contribute to the variability in nevirapine clearance. 15
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